Newsletter Volume 38, Number 4, 2023
Introduction
The rainy season has just ended, and we have had eight consecutive days of extremely hot weather with temperatures exceeding 35°C (95°F). In addition to the heat wave, we should pay attention to sudden changes in weather conditions caused by guerrilla torrential rains. Strong sunlight warms the air near the earth’s surface, causing updrafts that generate well-developed cumulonimbus clouds. These cumulonimbus clouds cause localized, short-lived, heavy rainfall, which is called a guerrilla downpour. Compared to typhoons, guerrilla torrential rains are considerably smaller in scale, so even supercomputers are not yet able to predict them accurately. Therefore, the most accurate way to predict a guerrilla downpour is to check the actual conditions that are occurring at the time of the downpour. Please be careful of sudden and unpredictable guerrilla downpours.
The 38th Annual Meeting of the Japanese Society of Pharmacokinetics, which will be held in Shizuoka at the end of September, is an international joint meeting with the Cytochrome P450 International Conference. The theme of the meeting is “Discovering New Knowledge and Techniques in Life Science and Drug Discovery -Learn from the Past, Know the Future-,” and it will be an opportunity to learn from the past and dance your heart out to the unpredictable future.
Starting with this issue of NL, a new five-part series, “Antibody Drug Conjugate (ADC) Pharmacokinetics Research,” will appear in the Journal. This is a must-see article that covers the modality of ADCs and the characteristics of their pharmacokinetics. We hope you will enjoy the article. (T.H.)
Topics
Check it easily with a short movie! Highlights of the General Symposium at the 2023 ICCP450/JSSX International Joint Convention in Shizuoka, Japan
With 32 general symposia being held in parallel at the ICCP450/JSSX Joint Convention (Shizuoka: Sept. 25 – 29), it is hard to know which one to go to. To help you plan your schedule, we have prepared a short video introducing each symposium. Please watch it to get the gist of each symposium. Please watch the videos to get the gist of each symposium.
Antibody Drug Conjugate (ADC) Pharmacokinetic Studies
Part 1: Introduction: Concept and Components of ADCs
Tsuyoshi Karibe, Laboratory of Pharmacokinetics, Daiichi Sankyo Company, Limited
Introduction! This is the second installment of the introduction to pharmacokinetic research in the research and development of new modality, following “Cell Therapy”, and this time we will focus on “Antibody Drug Conjugate (ADC)”. The number of approved drugs in the field of oncology has increased dramatically in the past few years, and it is no exaggeration to say that “ADC” is now a validated modality as well as “small molecules” and “antibodies,” which are its base. In this series, we would like to introduce how to evaluate the characteristic properties of “ADCs” from the pharmacokinetic point of view, including our own research activities. In the first article, we will explain the modality of “ADC” as an introduction to this series. … ( To be continued at NL website / Members only )